Posters & Publications

Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Presented at: 2020 Society for Immunotherapy of Cancer (SITC)

Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcγR- and TLR- signaling and enables safe systemic administration

Presented at: 2020 Society for Immunotherapy of Cancer (SITC)

Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models

Presented at: 2020 Society for Immunotherapy of Cancer (SITC)

HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner

Presented at: 2019 Society for Immunotherapy of Cancer (SITC)

TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity

Presented at: 2019 American Association for Cancer Research (AACR)

Systemic immunity is required for effective cancer immunotherapy

Spitzer MH et al., Cell (2017)

Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity

Carmi Y, et al., Nature (2015)